Emerging 2026 Research Is Pointing to a New Root Cause of AFib Stroke Risk — and What Can Finally Be Done About It
I've been treating men on blood thinners for AFib for twenty years. For most of those twenty years, the field didn't have a clear answer for why they still felt like walking time bombs.
That's changed.
Over the last several years, a body of research has been building across cardiology, stroke, and blood-clotting journals — and in 2026, what was once a fringe hypothesis is becoming the broadly accepted explanation: a stroke on a blood thinner is, at its core, a condition of the old fibrin the pill was never built to clear.
You don't need to take my word for it. Open a new tab and type "can you still have a stroke on eliquis" into Google. Look at what comes up.
Medical journals. Research universities. Clinical reviews. This isn't fringe. It's where the science has landed.
Here's what that actually means.
What Fibrin Buildup Is
Right inside your blood, there's a sticky, living protein called fibrin. Think of it as a strip of wet gauze, but alive, and laid along every artery, every heart chamber, and every tiny vessel in your body, sealing every nick from the inside.
When you're young and your blood is healthy, fibrin is patched on and swept off within hours. Your blood races up to your brain without a snag. You don't feel it. It does its job invisibly.
But your blood needs a specific clean-up enzyme to stay that way — the dissolver it uses to cut old fibrin down, keep the artery wide, and keep blood moving through every chamber of your heart.
As you age, that clean-up slows down. Your body makes less of what dissolves fibrin. An irregular heartbeat, high pressure, sitting, and accumulated wear speed the process up. The fibrin stops getting swept away.
So it piles up.
Piled-up fibrin loses its soft, temporary quality. It hardens. It narrows. And as it narrows, it begins to physically choke everything it lines — including the arteries that carry blood up your neck to your brain.
And once you understand that mechanism, every symptom you've been carrying makes sense.
The cold hands, even in July
Fibrin lines the small vessels from your fingertips to your toes. When old fibrin piles up there while your blood thinner only stops new clots, your hands go cold in July and your doctor calls it "controlled" — because the pill never touched what's already there.
The legs like wet sandbags
The fibrin in your leg arteries sits on the long road your blood travels, the stretch your blood thinner never sweeps. When it narrows, your legs drag like wet sandbags.
The 2 a.m. pulse check
When fibrin piles up in the arteries feeding your brain, those arteries become the weak spot. Every skipped beat feels like the start of a stroke because the road to your brain is being narrowed before the blood even reaches it.
The tiredness that never lifts
When your arteries are narrowed, every heartbeat costs more energy than it should. By the end of the day, you're exhausted and your doctor blames the beta-blocker — but your heart was pushing blood through resistance from the inside.
The Research Behind It
This isn't a single study or a fringe theory. It's a converging body of work across multiple labs and journals:
In 18,201 AFib patients, 1.27% a year on apixaban still had a stroke or a clot — better than warfarin's 1.60%, but never zero.
Strokes in AFib patients already on a blood thinner are not uncommon — and the risk of another stays high.
In lab rats, nattokinase reopened an artery already blocked by a clot, restoring 62% of blood flow — plasmin managed only 16%.
Reviewed side by side with blood thinners, nattokinase thins blood, dissolves clots and directly degrades fibrin.
These are a few papers out of dozens. All peer-reviewed, all in PubMed, all published in major medical journals.
The 2024 review is the most recent — and it confirms, side by side with blood thinners, that nattokinase directly breaks down fibrin and dissolves blood clots.
The findings are public. They've just been slow to reach clinical practice.
Why Nothing You've Tried Has Worked
Eliquis, Xarelto, warfarin — every prescription you've been handed for your AFib is designed to do the same thing: keep the next new clot from forming.
None of them touch the reason your stroke risk never hits zero in the first place. The old fibrin is still there, still narrowing every artery it lines, still building the blockage your blood thinner was only ever built to slow.
That's why the dread never lifts. Nothing in your pill organizer was ever pointed at the old fibrin.
What Sweeping Out The Old Fibrin Actually Requires
It's the same mechanism, in reverse.
Your fibrin piled up because your body stopped making enough of what dissolves it. Give that back, and the old fibrin dissolves. As it dissolves, the artery widens. As it widens, it releases its choke on the blood headed to your brain — and the cold hands, the heavy legs, and the 2 a.m. dread start to resolve at the source.
There's no shortcut around this. You can't thin the blood enough, or check your pulse often enough, to fix a problem that lives inside the artery wall. The old fibrin has to be swept out from the inside, with the enzyme your body ran short on, while your blood thinner keeps holding the brake.
I spent years recommending the closest things I could find — fish oil, turmeric, 2,000 FU nattokinase off Amazon. I kept coming back to the same conclusion: the ingredients existed, but nothing was putting them together correctly.
So in early 2025, I decided to build the formulation myself.
I teamed up with a small group of stroke-prevention and blood-clotting researchers, and we spent the better part of a year working through the literature, sourcing the right forms of each ingredient, and testing the formulation. By the end of 2025, we had it.
Noverly Nattokinase
The formulation centers on three core actives — chosen because they're each in the form that actually reaches the artery wall.
They're supported by bromelain, turmeric, aged garlic, grape seed, and dandelion root — a matrix that helps the actives absorb and reach the artery wall.
Every ingredient is research-backed. Every dose is based on what the peer-reviewed literature supports. Nothing is in there for marketing — no underdosed enzyme, no maltodextrin filler, no ingredients that look impressive on a label but don't reach the artery.
What Happened With The First 1,000 Customers
In early 2026 we ran an initial launch and tracked outcomes from our first 1,000 customers across the first 90 days on the protocol. Among those who completed the full 90 days:
These aren't clinical trial numbers. They're self-reported outcomes from real customers — most of whom had been on a blood thinner for AFib for over five years and had already tried everything else.
Most reported the shift starting between week three and week six. By day 90, the majority were describing it the same way: not a fear that had been managed, but a body that finally felt covered on both sides.
If you've been on a blood thinner long enough to know that controlled isn't the same as cleared out, Noverly is built for what you've actually been looking for.
Try it for 90 days.
If it doesn't work for you in that window, send it back. Full refund. No questions, no fine print, no return process designed to wear you down. I don't want patients paying for something that isn't helping them.